Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml
Geburtshilfe Frauenheilkd 2021; 81(04): 373-375
DOI: 10.1055/a-1348-3454
DOI: 10.1055/a-1348-3454
DGGG
Mitteilungen aus der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG)
Positionspapier vom 27.01.2021 – COVID-19-Schutzimpfung bei PatientInnen mit aktiver Krebserkrankung
![](https://www.thieme-connect.de/media/gebfra/202104/lookinside/thumbnails/10-1055-a-1348-3454_gfm2021_04_dggg_02-1.jpg)
Die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), die Deutsche Gesellschaft für Senologie (DGS) sowie die Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) sind an einem Positionspapier zur COVID-19-Schutzimpfung bei PatientInnen mit aktiver Krebserkrankung beteiligt, das federführend von der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) erarbeitet wurde.
Publication History
Article published online:
14 April 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 WHO Coronavirus Disease (COVID-19) Dashboard. Data last updated: 2021/1/26, 4 : 50 pm CET. Online: https://covid19.who.int/
- 2 Online: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/nCoV_node.html;jsessionid=57B91F291A3125A8213D01E6115FE532.internet081
- 3 Online: https://www.dgim.de/fileadmin/user_upload/PDF/Publikationen/Archiv/Positionspapiere_und_Stellungnahmen/FINAL_DGIM_20210107_Stellungnahme_STIKO-COVID-19.pdf
- 4 Giesen N, Sprute R, Maria Rührich M. et al. Evidence-based Management of COVID-19 in Cancer Patients – Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer 2020; 140: 86-104 doi:10.1016/j.ejca.2020.09.009
- 5 Von Lilienfeld-Toal M, Giesen N, Greinix H. et al. Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen. Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status Januar 2021. Online: https://www.onkopedia.com/de/onkopedia/guidelines/coronavirus-infektion-covid-19-bei-patienten-mit-blut-und-krebserkrankungen/@@guideline/html/index.html
- 6 Cook G, John Ashcroft A, Pratt G. et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol 2020; 190: e83-e86 doi:10.1111/bjh.16874
- 7 Dai M, Liu D, Liu M. et al. Patients With Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study During the COVID-19 Outbreak. Cancer Discov 2020; DOI: 10.1158/2159-8290.CD-20-0422.
- 8 Grivas P, Warner JL, Shyr Y. et al. Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
- 9 Kuderer NM, Choueiri TK, Shah DP. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395: 1907-1918 doi:10.1016/S0140-6736(20)31187-9
- 10 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337 doi:10.1016/S1470-2045(20)30096-6
- 11 Mehta V, Goel S, Kabarriti R. et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov 2020; DOI: 10.1158/2159-8290.CD-20-0516.
- 12 Palmieri C, Turtle L, Docherty A. et al. Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. Ann Oncol 2020; 3 (Suppl. 04) S934-S973 doi:10.1016/annonc/annonc289 update January 2021 (personal communication)
- 13 Passamonti F, Cattaneo C, Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Hematol 2020; 7: e737-e747 doi:10.1016/S2352-3026(20)30251-9
- 14 Tian J, Yuan X, Xiao J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893-903 doi:10.1016/S1470-2045(20)30309-0
- 15 Wise-Draper T, Desai A, Elkrief A. et al. Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
- 16 Saini KS, Tagliamento M, Lambertini M. et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer 2020; 139: 43-50 doi:10.1016/j.ejca.2020.08.011
- 17 COVID-19 and Cancer Consortium (CCC19). Online (Stand: 23.01.2021): https://public.tableau.com/profile/reboot.rx%23!/vizhome/covidcancer/PublishedClinicalStudies
- 18 Venkatesulu BP, Chandrasekar VT, Girdhar P. et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv 2020; DOI: 10.1101/2020.05.27.20115303.
- 19 Rüthrich MM, Giessen-Jung C, Borgmann S. et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2020; DOI: 10.1007/s00277-020-04328-4. update January 2021 (personal communication)
- 20 Online: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.pdf?blob=publicationFile
- 21 Williamson EJ, Walker AJ, Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436 doi:10.1038/s41586-020-2521-4
- 22 Wood WA, Neuberg DS, Thompson JC. et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 2020; 4: 5966-5975 doi:10.1182/bloodadvances.2020003170
- 23 De Joode K, Dumoulin DW, Tol J. et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer 2020; 141: 171-184 doi:10.1016/j.ejca.2020.09.027
- 24 Bundesministerium für Gesundheit. Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2(Coronavirus-Impfverordnung–CoronaImpfV). Online: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Coronavirus/Verordnungen/CoronaImpfV_-_De_Buette.pdf
- 25 Giesen N, Sprute R, Rüthrich M. et al. for the COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 Update of AGIHO guideline on evidence-based management of COVID-19 in cancer patients regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer 2021; 147: 154-160
- 26 Avanzato VA, Matson JM, Seifert SB. et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020; 183: 1901-1912 doi:10.1016/j.cell.2020.10.049
- 27 Online: https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/coronavirus/prolongierte-virusausscheidung-shedding-von-sars-cov-2_20201114.pdf/view